Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw

Yun-Ho Kim¹, Han-Kyu Park¹, Na-Rae Choi¹, Seong-Won Kim¹, Gyoo-Cheon Kim², Dae-Seok Hwang¹, Yong-Deok Kim¹, Sang-Hun Shin¹, Uk-Kyu Kim¹
Departments of ¹Oral and Maxillofacial Surgery and ²Oral Anatomy, School of Dentistry, Pusan National University, Yangsan, Korea

Abstract (J Korean Assoc Oral Maxillofac Surg 2017;43:16-22)

Objectives: Bisphosphonate is the primary cause of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Bisphosphonates are eliminated from the human body by the kidneys. It is anticipated that bisphosphonate levels in the body will increase if the kidney is in a weak state or if there is systemic disease that affects kidney function. The aim of this study was to analyze the relevance of renal function in the severity of BRONJ.

Materials and Methods: Ninety-three patients diagnosed with BRONJ in Pusan National University Dental Hospital from January 2012 to December 2014 were included in this study. All patients underwent a clinical exam, radiographs, and serologic lab test, including urine analysis. The patient’s medical history was also taken, including the type of bisphosphonate drug, the duration of administration and drug holiday, route of administration, and other systemic diseases. In accordance with the guidelines of the 2009 position paper of American Association of Oral and Maxillofacial Surgeons, the BRONJ stage was divided into 4 groups, from stage 0 to 3, according to the severity of disease. IBM SPSS Statistics version 21.0 (IBM Co., USA) was used to perform regression analysis with a 0.05% significance level.

Results: BRONJ stage and renal factor (estimated glomerular filtration rate) showed a moderate statistically significant correlation. In the group with higher BRONJ stage, the creatinine level was higher, but the increase was not statistically significant. Other factors showed no significant correlation with BRONJ stage. There was a high statistically significant correlation between BRONJ stage and ‘responders group’ and ‘non-responders group,’ but there was no significant difference with the ‘worsened group.’ In addition, the age of the patients was a relative factor with BRONJ stage.

Conclusion: With older age and lower renal function, BRONJ is more severe, and there may be a decrease in patient response to treatment.

Key words: Osteomyelitis, Bisphosphonate-associated osteonecrosis of the jaw, Chronic renal diseases

[paper submitted 2016. 9. 29 / revised 2016. 12. 2 / accepted 2016. 12. 25]

I. Introduction

Bisphosphonate is the most widely used therapeutic agent for osteoporosis in South Korea. It has been in the spotlight over the last few years as a therapeutic agent for metabolic disease, spinal cord compression, pathologic fractures, pain, etc. It is known that a certain amount of bisphosphonate administered systemically is absorbed by the bone tissue, and that the rest is discharged through the kidneys. Bisphosphonate is discharged through 3 pathways: (1) glomerular filtration rate (GFR); (2) renal tubular secretion; and reabsorption within the renal tubular lumen. The excretion of bisphosphonate is closely associated with the renal clearance rate and is thought to be closely tied to the patient’s renal function or systemic diseases that are affecting renal function. Since Marx first reported bisphosphonate-related osteonecrosis of the jaw (BRONJ) in 2003, it has been the topic of many studies. In the 2009 position paper of the American Association of Oral and Maxillofacial Surgeons (AAOMS), BRONJ was defined according to the following criteria: (1) past or current bisphosphonate therapy history; (2) exposed necrotic bone present in the jaw area, present for more than 8 weeks; and (3) no radiation therapy in the jaw. Below are the
detailed criteria for staging\(^9\). (Table 1)

Silva et al.\(^{10}\) reported that the incidence of BRONJ increased when more than a certain level of zoledronate was administered. In a study conducted by Manzano-Moreno et al.\(^{11}\), as the duration of bisphosphonate administration increased, the differentiation of the osteoblast-like cells decreased, and cell death and necrosis occurred. The bisphosphonate deposited in the bone is isolated only if the bone is re-absorbed, and the half-life is about 10 years\(^6\). Therefore, as the duration of bisphosphonate treatment increases, the concentration of deposited bisphosphonate increases. Moreover, as the patient’s renal function decreases, the deposition of bisphosphonate will increase. Thus, BRONJ is expected to become more severe.

The purpose of this study was to identify the relationship between severity of BRONJ and renal function by comparing the results of the clinical tests, radiological examinations, serologic tests, and medical records of patients assessed for BRONJ. Renal function was assessed based on the criteria of the National Kidney Foundation (NKF) and International Society of Nephrology (ISN)\(^{12,13}\). (Table 2) Through this investigation, we intended to identify the factors that significantly affect the severity of each group.

### II. Materials and Methods

**1. Subjects**

In this study, we analyzed 106 patients who had been diagnosed with BRONJ through clinical tests and radiography and who had been treated at the Department of Oral and Maxillofacial Surgery of the Pusan National University Dental Hospital (Yangsan, Korea) within the period from January 2012 to December 2014. Of these patients, 13 had an ambiguous bisphosphonate formulation component or had discontinued regular follow-up. For the remaining 93 patients,

---

**Table 1. Staging system of the American Association of Oral and Maxillofacial Surgeons for BRONJ\(^9\)**

| Stage | Features |
|-------|----------|
| At risk | No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates |
| Stage 0 | No clinical evidence of necrotic bone, but non-specific clinical findings and symptoms |
| Stage 1 | Exposed and necrotic bone in patients who are asymptomatic and have no evidence of infection |
| Stage 2 | Exposed and necrotic bone associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage |
| Stage 3 | One or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone, pathologic fracture, extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible |

**Table 2. CKD: a clinical action plan**

| Stage | Description | GFR (mL/min/1.73 m\(^2\)) | Action |
|-------|-------------|--------------------------|--------|
| 1     | Kidney damage with a normal or ↑GFR | ≥60 (with CKD risk factors) | Diagnosis and treatment, treatment of comorbid conditions, slow progression, reduce CVD risk |
| 2     | Kidney damage with a mild ↓GFR | 60-89 | Estimate progression |
| 3     | Moderate ↓GFR | 30-59 | Evaluate and treat complications |
| 4     | Severe ↓GFR | 15-29 | Prepare for kidney replacement therapy |
| 5     | Kidney failure | <15 (or dialysis) | Replacement (if uremia present) |

(CKD: chronic kidney disease, GFR: glomerular filtration rate, CVD: cranial vascular disease)
the type of bisphosphonate administered, the duration of its administration, drug holiday timing, administration route, and presence of systemic diseases were examined through clinical tests and medical history. In addition, the following serologic tests were performed: liver function test (LFT), renal function test (RFT), electrolyte test, C-reactive protein (CRP) test, HbA1c test, and C-telopeptide crosslink (CTX) test. For radiological examination, panoramic radiography and cone-beam computed tomography were conducted.

The study was approved by the Institutional Review Board of the Pusan National University Dental Hospital (PNUDH-2016-007).

2. Methods

For all patients, the medical history and serologic test results were recorded, and the panoramic radiography and cone-beam computed tomography, which were performed at the initial examination, were analyzed. The presence of an exposed bone determined through visual inspection and palpation, the finding of an infection, the size of the lesion, and the clinical symptoms were classified. The stage of BRONJ was based on the 2009 AAOMS position paper (Table 1) and was determined based on the analyzed medical records and radiographic images. The systemic diseases that can affect the renal function of the patients were roughly classified into heart disease, diabetes, liver disease, thyroid disease, and kidney disease. For arithmetic evaluation, the estimated glomerular filtration rate (eGFR) was calculated based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation (2009)\(^9\), and the CKD stage was also determined based on the calculated eGFR value\(^12\).

Through consultation with physicians, 91 patients had an average drug holiday lasting 15.0 weeks before surgery. A total of 46 patients (50.5%) had a less-than-1-month drug holiday, and 20 patients (22.0%) had a 1- to 3-month drug holiday. A total of 25 patients (27.5%) had a more-than-3-month drug holiday, as suggested in the 2009 AAOMS position paper. After the surgery, all 93 patients stopped taking bisphosphonate\(^9,15\).

As in our previous study conducted by Park et al.\(^15\), after the drug holiday, for the stage 1 patients, conservative treatment was administered; for the stage 2 patients, sequestrectomy and curettage of soft tissue were performed; and for the stage 3 patients, including sequestrectomy and curettage of soft tissue, fistula closure, mandibulectomy, or mandibular reconstruction was performed. For the conservative treatment, antibiotic treatments were administered, along with oral cleaning using a sanitizer (0.12% chlorhexidine), as suggested in the treatment strategy cited in the 2009 AAOMS position paper. For the antibiotic, penicillin was selected as the first-choice medication. Oral hygiene instruction was also offered, and follow-up examination was conducted every 2 weeks.

Evaluation of each group for prognosis was conducted 6 months after the start of treatment. For evaluation, if pain, infection, re-exposure of the bone necrosis site, and fistula formation were not observed and the patients showed a good treatment prognosis, the patient was assigned to the responder group. If no clinical and radiological differences were shown before or after the treatment or if BRONJ recurred, the patient was assigned to the non-responder group. If the clinical symptoms (pain, extraoral fistula, pathological fractures, etc.) became worse, the patient was assigned to the worsened group\(^15\).

Regression analysis was performed at a 0.05% significance level for the BRONJ stage and the significant serologic markers. All statistical analyses were performed using the IBM SPSS Statistics version 21.0 (IBM Co., Armonk, NY, USA).

III. Results

Of the 93 patients, 1 was male and 92 were female. Based on the AAOMS diagnosis criteria, there were 15 patients at stage 1, 53 patients at stage 2, 25 patients at stage 3, and no patient at stage 0. The mean age was 73.2 years (range, 51-86 years). As for the type of bisphosphonate that was administered, alendronate was administered to 54 patients (58.1%), risedronate to 15 patients (16.1%), ibandronate to 17 patients (18.3%), pamidronate to 4 patients (4.3%), and zoledronate to 3 patients (3.2%). For the administration route, 80 patients (86.0%) had oral administration and 13 patients (14.0%) had intravenous administration. The average duration of administration was 5.5 years (range, 0.25-20 years). The mean eGFR calculated using the CKD-EPI creatinine equation was 65.9 mL/min/1.73 m\(^2\). The 83 patients who responded during the 6 months after treatment were assigned to the responder group, the 5 patients who did not respond to the treatment were assigned to the non-responder group, and 5 patients were assigned to the worsened group.

To determine the correlations between BRONJ stage and the impact factors, regression analysis was used. Among all impact factors, age and eGFR were observed to have a significant correlation with BRONJ stage. In particular, we focused...
on blood creatine level, which is the representative measure of kidney function. As the severity of BRONJ increased, the patient’s creatinine level increased, but the change was not statistically significant. (Tables 3, 4)

There was no definite effect of serum calcium level, serum albumin level, type of bisphosphonate, route of administration, duration of medication or drug holiday, presence of a systemic disease, or CTX level on BRONJ stage.

To determine the correlation between the degree of response to treatment and BRONJ stage, the patients were assigned to the responder, non-responder, or worsened group. The responder group showed a lower BRONJ stage compared to the non-responder group, and this difference was statistically significant. (Table 5)

IV. Discussion

Bisphosphonate is one of the most widely prescribed drugs for patients with osteoporosis. It increases the bone density by depositing serum calcium in the bone, reduces the bone turnover rate, and decreases the risk of pathologic fracture. As bisphosphonate is generally excreted through the kidneys; however, if an excessively high plasma level is maintained, it may have a side effect on the kidneys. The incidences of osteoporosis and kidney failure are both known to increase with aging. Considering this, the relationship between BRONJ and renal function needs to be addressed.

BRONJ was first published in the 2007 AAOMS position paper, and the criteria for its stage and drug holiday were suggested in the 2009 position paper. Moreover, in 2014, AAOMS published its third position paper on this disease. In the paper, the definition of BRONJ was changed to “necrosis of the jaw” due to the administration of anti-absorption drugs, anti-angiogenic therapy, etc., as well as bisphosphonate administration, and it was renamed “medication-related osteonecrosis of the jaw (MRONJ)”. As such drugs also go through the kidneys’ excretion process, a healthy renal function is considered important in the pharmacokinetic aspect based on the drug concentration.

In the kidney disease: Improving the Global Outcome (KDIGO) group of NKF and ISN, if the eGFR is less than 60 mL/min/1.73 m² for more than 3 months, regardless of the reason, and if proof of renal damage is found in the blood, on blood creatine level, which is the representative measure of kidney function. As the severity of BRONJ increased, the patient’s creatinine level increased, but the change was not statistically significant. (Tables 3, 4)

There was no definite effect of serum calcium level, serum albumin level, type of bisphosphonate, route of administration, duration of medication or drug holiday, presence of a systemic disease, or CTX level on BRONJ stage.

To determine the correlation between the degree of response to treatment and BRONJ stage, the patients were assigned to the responder, non-responder, or worsened group. The responder group showed a lower BRONJ stage compared to the non-responder group, and this difference was statistically significant. (Table 5)

| Table 3. The mean values of several impact factors of BRONJ by stage |
|-------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
| Stage                  | Age (yr) | AST (IU/L) | ALT (IU/L) | ALP (IU/L) | BUN (mg/dL) | Creatinine (mg/dL) | eGFR (mL/min/1.73 m²) |
| Stage 1                | 69.38    | 29.38    | 21.06    | 177.25    | 13.61    | 0.73    | 74.56    |
| Stage 2                | 73.43    | 28.94    | 20.13    | 167.45    | 16.23    | 0.78    | 65.06    |
| Stage 3                | 75.69    | 20.73    | 12.54    | 159.65    | 15.50    | 0.89    | 62.62    |
| P-value                | 0.002*   | 0.021*   | 0.808    | 0.329     | 0.513    | 0.143   | 0.008*   |

*P<0.05.  
P-value by regression analysis.

Table 4. The results of regression analysis for several impact factors with BRONJ stage

| Factors   | R² | t    | Beta | P-value |
|-----------|----|------|------|---------|
| Age       | 0.070 | 2.638 | 0.264 | 0.010* |
| AST       | 0.056 | −2.344 | −0.236 | 0.021* |
| ALT       | 0.055 | −2.334 | −0.235 | 0.022* |
| ALP       | 0.008 | −0.886 | −0.091 | 0.378   |
| BUN       | 0.008 | 0.871 | 0.090 | 0.386   |
| Creatinine| 0.036 | 0.190 | 1.863 | 0.066*  |
| eGFR      | 0.045 | −2.083 | −0.211 | 0.040*  |

(BRONJ: bisphosphonate-related osteonecrosis of the jaw, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, BUN: blood urea nitrogen, eGFR: estimated glomerular filtration rate)  
*P<0.05.

Table 5. The results of regression analysis about the degree of response to treatment

| No. of patients | Mean stage | R²  | T     | Beta  | P-value |
|-----------------|------------|-----|-------|-------|---------|
| Responder       | 83         | 2.04| 0.101 | −3.198| −0.318  | 0.002*  |
| Non-responder   | 5          | 3.00| 0.108 | 3.322 | 0.329   | 0.001*  |
| Worsened        | 5          | 2.40| 0.012 | 1.034 | 0.108   | 0.304   |

*P<0.05.

Yun-Ho Kim et al: Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 2017
The incidence of BRONJ, but once BRONJ occurs, the effects of the drug itself or its administration method can increase and after the surgery, respectively, was suggested. The study conducted by Damm and Jones and published in 2013 also proposed that a 2-month drug holiday period is necessary for the complete excretion of serum bisphosphonate through the kidneys and for the full recovery of the activity of the osteoclasts. On the other hand, the 2014 AAOMS position paper stated that the scientific evidence for the need to discontinue bisphosphonate administration was not sufficient. In this study, no statistical association was found between the BRONJ stage and the washout period, but the BRONJ stage was found to be correlated with the number of patients in both the responder and non-responder groups.

In the study, the responder group showed the lowest mean BRONJ stage, with generally low BRONJ stages. Based on this, we concluded that the severity of BRONJ may not decrease despite a long drug holiday period, and that the probability of responding to the treatment may be low.

The fact, the non-responder group showed the highest mean BRONJ stage, and the distribution of higher BRONJ stages runs counter to the hypothesis of this study. Such a result may be due to the small number of patients in both the non-responder and worsened groups (5 patients, respectively). To establish clear criteria for further guideline, a long-term study based on a large sample size is necessary.

In the study conducted by Marx et al., the patients were assigned to the high-risk group if their serum CTX level was less than 100 pg/mL, to the moderate-risk group if their serum CTX level was 100-150 pg/mL, and to the low-risk group if their serum CTX level was higher than 150 pg/mL. In the study conducted by Song et al., however, the value obtained through the risk assessment using the CTX level did not have a significant correlation with the severity of BRONJ. Grbic et al. reported that the association of CTX level with BRONJ was not sufficient in their study, although a low CTX level was maintained through the long-term administration of zoledronic acid. It was also found in our study that CTX was not significantly correlated with the BRONJ stage.

Patient age is closely associated with the development of BRONJ as well as with renal function. The 2009 AAOMS position paper stated that the use of steroids due to another disease or the risk of osteoporosis due to menopause or aging might increase. According to Park et al., Bamias et al., and Hoff et al., the physiological effect of aging seems to be associated with BRONJ. In this study, age and decreased renal function were confounding factors, but occurring result of BRONJ also was obtained when analyzing each of the two factors separately.

On the other hand, Baqain et al. and Vahtsevanos et al. reported no statistically significant correlation between aging and BRONJ stage. In the present study, patient age did show a statistically significant association with the BRONJ stage.
A typical method of evaluating renal function is calculating the GFR, which can be simply estimated using the creatinine value. With regard to the relationship between the kidneys and bisphosphonate, Markowitz et al.\textsuperscript{34,35} reported that kidney failure occurred in the patients in their study after injection of bisphosphonate, but Gifre et al.\textsuperscript{21} reported that kidney failure occurred in only 10\% of the patients who received bisphosphonate for at least 1 year.

According to Suresh et al.\textsuperscript{36}, in patients with higher than stage 4 CKD, the bisphosphonate administration dose must be reduced or the drug should not be prescribed at all, and in patients with lower than stage 3 CKD, the same dose as that for the general population can be prescribed. According to the aforementioned literature, the incidence of kidney failure due to bisphosphonate administration is higher in patients with lowered renal function, and as such, high-dose bisphosphonate can easily accumulate in the body. Moreover, due to the high-dose bisphosphonate deposit, the probability of kidney failure recurrence increases, and the cycle is repeated. In our study, the BRONJ stage was significantly associated with eGFR. As the CKD stage was also determined according to the eGFR value, CKD would also be associated. Therefore, as the renal function remarkably decreases, CKD stage is higher, and the severity of BRONJ might increase.\cite{Table 2} In addition, we conclude that, as the severity of BRONJ increases, the patient’s response to the treatment decreases.\cite{Table 5} Taken together, our results suggest that decreased renal function will result in decreased patient response to the treatment.

In general, the systemic diseases that affect the renal function of patients are hypertension, diabetes, glomerulonephritis, infection, and steroid treatment for osteoarthritis management\textsuperscript{37}. In this study, however, heart disease, diabetes, liver disease, thyroid disease, and kidney disease were found not to have a statistically significant correlation with the BRONJ stage. This was illustrated by a case where the patient was unaware they had an aforementioned disease until diagnosed through clinical and serologic tests, and by a case where the patient did not have any of the aforementioned diseases but was taking a drug for preventive purposes. Additionally, there were cases with no detailed diagnosis, where the patient was completely cured after the surgery, continued to receive the drug and was not examined, or the duration of drug administration or treatment was not calculated. For significant results, more specific variables must be applied for each item. For the aforementioned items, long-term prognosis assessment and follow-up observation targeting a large number of patients are required, and the specifications of renal function and systemic disease will be necessary.

V. Conclusion

This study was conducted in 93 patients who had been diagnosed with BRONJ through clinical tests, radiography, and serologic tests at the Department of Oral and Maxillofacial Surgery of Pusan National University Dental Hospital from January 2012 to December 2014. This study aimed to identify the relationship between severity of BRONJ and renal function and to determine the factors that affect this relationship.

The BRONJ stage showed a significant correlation with the renal function value, the eGFR. In addition, the BRONJ stage was found to be significantly correlated with the responder and non-responder groups, but was not significantly correlated with the worsened group. Moreover, the BRONJ stage was found to be significantly correlated with patient age. Therefore, based on the results of our study, we conclude that old patients with remarkably lowered renal function are likely to have more severe BRONJ, and the degree of patient response to the treatment is likely to be low.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

ORCID

Yun-Ho Kim, http://orcid.org/0000-0002-3533-6693
Han-Kyul Park, http://orcid.org/0000-0002-6695-9156
Na-Rae Choi, http://orcid.org/0000-0002-5251-0825
Seong-Won Kim, http://orcid.org/0000-0002-9994-5121
Gyoo-Cheon Kim, http://orcid.org/0000-0003-3568-3529
Dae-Seok Hwang, http://orcid.org/0000-0001-6899-1769
Yong-Deok Kim, http://orcid.org/0000-0002-0467-6206
Sang-Hun Shin, http://orcid.org/0000-0003-1251-7843
Uk-Kyu Kim, http://orcid.org/0000-0003-1251-7843

References

1. Coleman RE. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer 2000;7:361-9.
2. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
3. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Toni-
no RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.

4. Park HM, Lee ES, Kim SM. The use of osteoporosis medications in Korea in 2008. Korean J Bone Metab 2009;16:87-93.

5. Miller PD. The kidney and bisphosphonates. Bone 2011;49:77-81.

6. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.

7. Wikipedia: Renal function [Internet]. [place unknown: publisher unknown]. [modified 2017 Feb 1; cited 2016 Sep 8]. Available from: https://en.wikipedia.org/wiki/Renal_function.

8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.

9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrtra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.

10. Silva PG, Ferreira Junior AE, Teófilo CR, Barbosa MC, Lima Junior RC, Sousa FB, et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch Oral Biol 2015;60:1237-45.

11. Manzano-Moreno FJ, Ramos-Torrejillas J, De Luna-Bertos E, Ruiz C, García-Martínez O. High doses of bisphosphonates reduce osteoclast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg 2015;43:396-401.

12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.

13. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Collapsing focal segmental glomerulosclerosis: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 2010;92:489-94.

14. Bamias A, Kastritis E, Bamia C, Moulakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.

15. Hoff A, Toth B, Altundag K, Guarneri V, Adamus A, Nooka A, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528.

16. Baqpin ZH, Sawar FA, Tumini Z, Bousn N, Al Edwan G, Jamal J, et al. Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 2010;92:489-94.

17. Vahtsevanos K, Kyrigidis A, Verrau E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62.

18. Markowitz GS, Appel GB, Fine PL, Fenevez AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.

19. Markowitz GS, Fine PL, Stack J, Kunis CL, Radhakrishnan J, Pal-eck W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.

20. O’Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758-65.

21. Gifre L, Peris P, Monegal A, Martinez-Ferrer A, Hernández MV, Guàrdens N. Effect of bisphosphonates on renal function in patients with osteoporosis. Eur Geriatr Med 2013;4:380-3.

22. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13.

23. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee [Internet]. Silver Spring (MD): US Food and Drug Administration; 2011 [cited 2016 Aug 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf.

24. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23.

25. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61:33-8.

26. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410.

27. Song JW, Kim KH, Song JM, Chun BD, Kim YD, Kim UK, et al. Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg 2011;37:1-8.

28. Gribic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 2010;141:1365-70.

29. Park W, Kim NK, Kim MY, Rhee YM, Kim HH. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int 2010;21:527-33.

30. Bamias A, Kastritis E, Bamia C, Moulakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.

31. Vahtsevanos K, Kyrigidis A, Verrau E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62.

32. Markowitz GS, Appel GB, Fine PL, Fenevez AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.

33. Markowitz GS, Fine PL, Stack J, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.

34. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014;53:19-31.

35. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. The effectiveness of the surgical approach and drug-holiday on the treatment of bisphosphonate related osteonecrosis of the jaw patient. Int J Oral Maxillofac Surg 2015;44 Suppl 1:e275.

36. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.

37. Markowitz GS, Fine PL, Stack J, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.